BIOR Company Profile and Key Details

Q: Who are the executives of BIOR?

Mr. George GianakopoulosSenior Vice President of SalesMr. Eric d'EsparbesExecutive Vice President & Chief Financial OfficerDr. Sharat Singh Ph.D.Head of ResearchEric FoxVice President of Fin. & Accounting & TreasurerDr. Paul Shabram M.B.A.Head of Technical OperationsMs. Robyn HattonHead of HRMr. Kevin Howe Ph.D.Senior Vice President of Strategic OperationsMr. Clarke Neumann J.D.Senior Vice President, Gen. Counsel & Sec.Mr. Troy SeelyeChief Information OfficerMr. Aditya P. Mohanty M.B.A.Chief Executive Officer & Director

NASDAQ : BIOR

Biora Therapeutics

$0.22

At Close 4:00 PM

Not Actively Trading

55.02

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Biora Therapeutics, Inc. (BIOR) stock remained unchanged at $0.22 a share on OTC. The stock opened at $0.22, fluctuating between $0.22 to $0.22 during the session.

Stock Snapshot

0.22

Prev. Close

994.99K

Market Cap

0.22

Day Low

0.6111111111111112

P/E Ratio

0.36

EPS (TTM)

-1.96

Cash Flow per Share

0.22

Open

4.52M

Number of Shares

0.22

Day High

55.65%

Free Float in %

-4.09

Book Value

169.45K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 18, 2025	0.22	0.22	0.22	0.22	0
Sep 15, 2025	0.22	0.22	0.22	0.22	0
Sep 11, 2025	0.22	0.22	0.22	0.22	0
Sep 08, 2025	0.22	0.22	0.22	0.22	0
Sep 04, 2025	0.22	0.22	0.22	0.22	0
Sep 02, 2025	0.22	0.22	0.22	0.22	169.45K
Aug 26, 2025	0.22	0.22	0.22	0.22	0
Aug 22, 2025	0.22	0.22	0.22	0.22	169.45K
Aug 15, 2025	0.22	0.22	0.22	0.22	0
Aug 12, 2025	0.22	0.22	0.22	0.22	0
Aug 11, 2025	0.22	0.22	0.22	0.22	0
Aug 08, 2025	0.22	0.22	0.22	0.22	0
Aug 06, 2025	0.22	0.22	0.22	0.22	0
Aug 05, 2025	0.22	0.22	0.22	0.22	0
Aug 04, 2025	0.22	0.22	0.22	0.22	0
Jul 31, 2025	0.22	0.22	0.22	0.22	0
Jul 30, 2025	0.22	0.22	0.22	0.22	0
Jul 29, 2025	0.22	0.22	0.22	0.22	0
Jul 28, 2025	0.22	0.22	0.22	0.22	169.45K
Jul 25, 2025	0.22	0.22	0.22	0.22	0

Contact Details

San Diego, CA 92122

United States

https://www.bioratherapeutics.com 855 293 2639

About Company

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $0.15 and $0.38. With a market capitalization of about $994.99 thousand, Biora Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.28). Key stats such as the average daily volume over the past year has been around 60.81 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Biora Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Aditya Mohanty, the company employs approximately 58 people and listed since June 19, 2020. Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics.

Technical Performance

BIOR has shown weak momentum, losing -66.28% over the past week and -91.51% over the past quarter, though year-to-date performance is down -95.85%. Short-term trend indicators are bullishly aligned (SMA20 -68.09%, SMA50 -83.03%, SMA200 -91.3%). The stock’s 14-day RSI is 18.88 (weak momentum), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.19% below its high and over 6.23% above its low.

Valuation Metrics

Biora Therapeutics, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 248.75 The P/FCF stands at -0.02, also above market averages.

Dividend & Fair Value

Biora Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.04. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Biora Therapeutics, Inc. generated EPS of -$13.03 over the past year. Five-year average earnings growth is 35.4%. The latest quarter delivered EPS of -$6.08. The next quarter is forecast at -$3.50. Next year's EPS is expected at $74.58. Biora Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2024, missed forecasts by 57.92%. The prior quarter beat by -100.02%. Over the last six quarters, Apple has recorded several small beats. These include -19.35% in November 13, 2023.

Shareholding & Insider Activity

Biora Therapeutics, Inc. has 4.42 million shares outstanding. The public float is 2.52 million shares, elevated short interest at 5.55% of float. This equals 140.76 thousand shares. The short ratio is 5.51 days. Institutional investors hold 36.04% of the float. Insiders own 0.1%. Herschkowitz Samuel holds 46.60 million shares, Stylli Harry has 14.62 million shares and Athyrium Opportunities III Co-Invest 1 LP has 12.51 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Biora Therapeutics generated $4.00K in revenue, or $0.00 per share. Gross margin was -13775.00%, operating margin -1678575.00%, and net profit margin -3102875.00%. Returns are negative, with ROA at -397.61% and ROE at 122.38%.
On valuation metrics, Biora Therapeutics trades at a P/E of -0.00, P/S of 248.75 and P/B of -0.00. Liquidity is tight, with a current ratio of 0.30 and quick ratio of 0.30. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 75737.50 days. Debt-to-equity is -0.47, supported by a cash flow-to-debt ratio of -1.02.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Biora Therapeutics posted revenue of $4.00K, down slightly from $305.00K in the prior quarter. Gross profit was - $551.00K (margin -13775.00%). Operating income was - $67.14M (margin -1678575.0%). Net income was- $124.12M (EPS - $7.87).
The company ended the quarter with $15.21M in cash and short-term investments, a total debt of $47.43M, and net debt of $32.22M. Total assets were $31.22M, with equity of - $101.42M. Financials further reflected weakness, with operating cash flow of - $48.50M, free cash flow of - $48.60M, and capital expenditures of - $103.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Biora Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 17, 2025, with a range of $0.00 to $0.34. 1-Year Outlook: Projected gain of 9.09%, with price at $0.24 by September 18, 2026, within a range of $0.00 to $2.69.

Key Takeaways

Biora Therapeutics, Inc. (NASDAQ:BIOR) shares are down -95.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biora Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $45.38, suggesting 20527.27% upside.

Frequently Asked Questions

What is the current Biora Therapeutics, Inc. (BIOR) stock price?

Biora Therapeutics, Inc. (OTC: BIOR) stock price is $0.22 in the last trading session. During the trading session, BIOR stock reached the peak price of $0.22 while $0.22 was the lowest point it dropped to. The percentage change in BIOR stock occurred in the recent session was 0% while the dollar amount for the price change in BIOR stock was $0.00.

BIOR's industry and sector of operation?

The OTC listed BIOR is part of Biotechnology industry that operates in the broader Healthcare sector. Biora Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BIOR?

Mr. George Gianakopoulos
Senior Vice President of Sales
Mr. Eric d'Esparbes
Executive Vice President & Chief Financial Officer
Dr. Sharat Singh Ph.D.
Head of Research
Eric Fox
Vice President of Fin. & Accounting & Treasurer
Dr. Paul Shabram M.B.A.
Head of Technical Operations
Ms. Robyn Hatton
Head of HR
Mr. Kevin Howe Ph.D.
Senior Vice President of Strategic Operations
Mr. Clarke Neumann J.D.
Senior Vice President, Gen. Counsel & Sec.
Mr. Troy Seelye
Chief Information Officer
Mr. Aditya P. Mohanty M.B.A.
Chief Executive Officer & Director

How BIOR did perform over past 52-week?

BIOR's closing price is 46.67% higher than its 52-week low of $0.15 where as its distance from 52-week high of $0.38 is -42.14%.

How many employees does BIOR have?

Number of BIOR employees currently stands at 58.

Link for BIOR official website?

Official Website of BIOR is: https://www.bioratherapeutics.com

How do I contact BIOR?

BIOR could be contacted at phone 855 293 2639 and can also be accessed through its website. BIOR operates from 4330 La Jolla Village Drive, San Diego, CA 92122, United States.

How many shares of BIOR are traded daily?

BIOR stock volume for the day was 169.45K shares. The average number of BIOR shares traded daily for last 3 months was 60.81K.

What is the market cap of BIOR currently?

The market value of BIOR currently stands at $994.99K with its latest stock price at $0.22 and 4.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	58
Beta	1.28
Sales or Revenue	$4.00K
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

BIOR Company Profile and Key Details

Biora Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics